[Click eStock] "SK Biopharmaceuticals, Steady Xcopri Profits... Target Price Raised"

KB Securities analyzed on August 6 that SK Biopharmaceuticals can achieve mid- to long-term growth as Xcopri profits remain steady. The investment opinion was maintained at 'Buy,' and the target price was raised from 140,000 won to 150,000 won.

SK Biopharmaceuticals recorded sales of 176.3 billion won and operating profit of 61.9 billion won in the second quarter. Compared to the same period last year, these figures increased by 31.6% and 137.6%, respectively. In particular, Xcopri US sales reached 154.1 billion won, showing rapid growth with a 46.5% increase year-on-year.

Kim Hyemin, a researcher at KB Securities, stated, "With the resolution of seasonal and temporary factors identified in the first quarter, a return to a high-growth trajectory has been confirmed." She also evaluated, "It is very encouraging that the average number of new monthly prescriptions (NBRx) in the second quarter has leveled up to around 1,800."

Kim further commented, "The expansion of cenobamate indications, age groups, and regions is proceeding as planned, and topline results from the PGTC Phase 3 clinical trial are expected within this year." She added, "We can also look forward to the submission of the IND for the Phase 1 clinical trial of the NTSR-1 target RPT candidate SKL35501."

She emphasized, "Although there is a perception that Xcopri is the sole growth driver, the company has consistently generated quality profits with sales exceeding 100 billion won every quarter since the second quarter of last year." She added, "Rather, I believe this is a company that investors can comfortably grow with from a mid- to long-term perspective."

This content was produced with the assistance of AI translation services.